Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$13.02 - $22.62 $1.97 Million - $3.42 Million
151,000 Added 33.93%
596,000 $8.11 Million
Q4 2022

Feb 14, 2023

BUY
$17.77 - $21.6 $7.91 Million - $9.61 Million
445,000 New
445,000 $8.69 Million
Q2 2022

Aug 15, 2022

SELL
$16.57 - $35.1 $7.47 Million - $15.8 Million
-450,776 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$26.23 - $47.86 $11.8 Million - $21.6 Million
450,776 New
450,776 $21 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.